Medidata vs Saama (2026)
The sponsor side comparison, and it is really a question about what the AI is sitting on. Medidata's capabilities are layered onto a clinical trial platform spanning tens of thousands of studies and millions of patients, with the most complete security disclosure located anywhere in this index, though the AI capabilities themselves are named rather than described and their oversight design is unpublished. Saama is the more specific AI proposition: models automating data quality review and query generation across more than 1,500 studies, with the company naming its own autonomy level for its agents, which is a disclosure almost nothing in this index offers. Neither publishes an attestation in Saama's case or an account of whether one sponsor's data trains models serving another, and for a pharmaceutical buyer that second question should be settled in contract before either is deployed.
- It names its own autonomy level for its agents, which almost nobody in this index does, so the buyer knows what the system decides rather than inferring it.
- Deployment scale is substantial and long standing across more than 1,500 studies at over 50 sponsors, and the model count and training scope are stated rather than described.
- Scope is bounded to sponsor side clinical development from study start through regulatory submission, which is a coherent product rather than a platform claim.
- The security disclosure is the most complete located anywhere in this index, which for a system holding trial data across tens of thousands of studies is the correct priority.
- The underlying platform spans an enormous body of historical trial and patient data, which is the asset the AI capabilities are built on and is not replicable.
- The regulatory posture for the platform is well documented for the regime that actually governs sponsor systems, rather than being argued from a device framework that does not apply.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Medidata and Saama are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Medidata | Saama |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Headquarters | New York, New York | Campbell, California |
| Website | medidata.com | saama.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Medidata its top capability grade on several axes, including Security Certifications and Trust Center, FDA and Regulatory Status and EHR and Interoperability Depth. Set against Saama, Medidata grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and Security Certifications and Trust Center. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Saama its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against Medidata, Saama grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Medidata or Saama?
On the axes where the AI Health Index separates them, Medidata grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and Security Certifications and Trust Center, and Saama grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Medidata leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Medidata and Saama differ most?
The widest separation the AI Health Index records between Medidata and Saama is on Model Supply Chain Disclosure, where Medidata grades B and Saama grades D. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Medidata and Saama grade the same?
The AI Health Index grades Medidata and Saama the same on several axes, including HIPAA and BAA Posture, AI Governance and Bias Disclosure and AI Liability and Recourse. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Medidata and Saama not disclosed?
At the last review, at least one of Medidata and Saama published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
Both vendors are graded on AI capabilities layered onto larger platforms, so a buyer is usually choosing a clinical data platform first and inheriting the AI second. Medidata publishes named capabilities with undescribed methods and no published oversight design for capabilities that differ substantially in how much they decide, and its otherwise exceptional disclosure posture does not extend to the AI layer.
Saama publishes a stated governance framework with nothing measurable behind it, no security attestation, and leaves the training question open, which is the central question when models are trained on sponsor data across many studies. Ask both explicitly whether one sponsor's data improves models serving another.